Literature DB >> 8276319

Protein S and C4b-binding protein levels in patients with stroke: implications for protein S regulation.

M E Carr1, S L Zekert.   

Abstract

Protein S circulates either free or bound to C4b-binding protein (C4b-BP). Only free protein S possesses cofactor activity for protein C, a physiologic anticoagulant. Deficiencies of either protein C or protein S are associated with increased thrombotic risk. Over a 23-month period, 40 patients with low free protein S were identified. Eight of these patients were found to have suffered a stroke. This study examined the relationship between total S, free S, and C4b-BP in 15 healthy adult volunteers, in 20 patients with normal protein S levels, in 40 patients with decreased free protein S levels, and in 8 patients with combined low free S levels and stroke. Total and free protein S and C4b-BP levels were determined using the method of Laurell. In healthy adults, free protein S increased with increasing total protein S (r = 0.60). In patients with normal free S, the total S level increased as C4b-BP increased (r = 0.74), and the free S level remained constant. In patients with low free S, total S did not increase with increasing C4b-BP. In stroke patients, the correlation between free S and total S was actually negative (r = -0.449). Evaluation of dissociation constants for the protein S-C4b-BP complex revealed enhanced binding in patients with low levels of free protein S. A non-C4b-BP protein S binding protein, a previously undescribed regulatory factor which modulates S binding to C4b-BP, or shifts in the amount of non-protein S binding C4b-BP are possible explanations of these results.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8276319     DOI: 10.1159/000216869

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  1 in total

1.  Plasma level of IL-6 and its relationship to procoagulant and fibrinolytic markers in acute ischemic stroke.

Authors:  Jae Woo Song; Kyung Soon Song; Jong Rak Choi; Shin Young Kim; Ji-Hyuk Rhee
Journal:  Yonsei Med J       Date:  2006-04-30       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.